Skip to search formSkip to main contentSkip to account menu

bivalirudin

Known as: Phe-Pro-Arg-Pro-(Gly)4-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu, Phe-Pro-Arg-Pro-(Gly)4-desulfohirudin-(53-64), Bivalirudinum 
A 20 amino acid long synthetic peptide with thrombin-specific anticoagulant properties. Bivalirudin reversibly binds thrombin, free as well as clot… 
National Institutes of Health

Related topics

Related topics

13 relations
Angina, UnstableDrug AllergyHemorrhagic DisordersMyocardial Ischemia

Narrower (4)

AngiomaxBG 8967HirulogHirulog-1

Broader (4)

AntithrombinsHirudinsPeptide FragmentsRecombinant Proteins

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Potential Contribution of Pleiotropic Effects of Direct Anticoagulants to Clinical Benefits
Clinical Development Phases I‐III Regulatory, Quality, Manufacturing 
2013
2013
Impact of Worsening Renal Dysfunction on the Comparative Efficacy of Bivalirudin and Platelet Glycoprotein IIb/IIIa Inhibitors: Insights From Blue Cross Blue Shield of Michigan Cardiovascular…
Background—Use of bivalirudin has been associated with a reduction in the incidence of bleeding in patients undergoing… 
2010
2010
Abstract 20882: Predictors of Suboptimal TIMI Flow after Primary Angioplasty for Acute Myocardial Infarction: Results from the HORIZONS-AMI Trial
Introduction: Not achieving TIMI 3 flow after primary PCI in ST-segment elevation myocardial infarction (STEMI) is strongly… 
2010
2010
Plasma exchange for heparin-induced thrombocytopenia: is there enough evidence?
Michael S. Avidan, MBBCh, FCASA† The perioperative management of patients who have a diagnosis of heparin-induced… 
2009
2009
Intracoronary bivalirudin for no reflow reversal: a second chance to treat this disorder?
No reflow, defined as failure to restore normal myocardial blood flow despite removal of coronary obstruction, is a not rare… 
2008
2008
Safety and Efficacy of Bivalirudin Monotherapy in Patients With Diabetes Mellitus and Acute Coronary Syndromes
Background In the ACUITY trial, 13,819 patients with moderateor high-risk acute coronary syndromes (ACS) were randomized to… 
2007
2007
Terapia anticoagulante en la circulación extracorpórea
La cirugia cardiaca es un area en la que la monitorizacion de la coagulacion es de gran importancia. Los procedimientos bajo… 
2005
2005
The effects of bivalirudin compared with those of unfractionated heparin plus eptifibatide on inflammation and thrombin generation and activity during coronary intervention
ObjectiveTo characterize effects of bivalirudin compared with unfractionated heparin plus eptifibatide on inflammation, and… 
1993
1993
Syrian hamster 3-hydroxy-3-methylglutaryl-coenzyme A reductase expressed in Escherichia coli: production of homogeneous protein.
When overexpressed in Escherichia coli, the catalytic domain of Syrian hamster 3-hydroxy-3-methylglutaryl-coenzyme A reductase… 
1986
1986
Structure of the amino-terminal end of mammalian elongation factor Tu.
Mixed sequence oligonucleotide probes complementary for peptides Thr-Ile-Glu-Lys-Phe-Glu and Asp-Tyr-Val-Lys-Asn-Met-Ile which…